NAPHTHOQUINE

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C24H28ClN3O
Molecular Weight	409.952
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)(C)NCC1=CC(NC2=CC=NC3=CC(Cl)=CC=C23)=C4CCCCC4=C1O

InChI

InChIKey=VEVMYTDOWUQLGI-UHFFFAOYSA-N

InChI=1S/C24H28ClN3O/c1-24(2,3)27-14-15-12-22(17-6-4-5-7-18(17)23(15)29)28-20-10-11-26-21-13-16(25)8-9-19(20)21/h8-13,27,29H,4-7,14H2,1-3H3,(H,26,28)

HIDE SMILES / InChI

Molecular Formula	C24H28ClN3O
Molecular Weight	409.952
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27075024
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/22363211

Naphthoquine is an antimalarial drug first synthesized in China in 1986 but which was not developed for clinical use until the late 1990s. This drug now is used in combination for treatment of Plasmodium Falciparum and Malaria. The use of anti-malarial drug combinations with artemisinin or with one of its derivatives is now widely recommended to overcome drug resistance in falciparum as well as vivax malaria. The fixed oral dose artemisinin-naphthoquine combination (ANQ, ARCO™) is a newer artemisinin-based combination (ACT) therapy undergoing clinical assessment.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
various P. falciparum strains 2 Target ID: various P. falciparum strains Sources: https://www.ncbi.nlm.nih.gov/pubmed/22363211	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Plasmodium falciparum malaria 63 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19671190	Curative		Phase IV 63	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Naphthoquine: An Emerging Candidate for Artemisinin Combination Therapy.	2016 May	27075024

Sample Use Guides

In Vivo Use Guide

Patients in this treatment arm will receive on Day 0 a single dose of standard treatment of artemisinin/naphthoquine (in a fixed oral dose of ARCO tablets). Treatment will be given under supervision. Each tablet of ARCO(artemisinin/naphthoquine) contains 125 mg artemisinin and 50 mg of naphthoquine. The total dose for adults will be 1000mg of artemisinin and 400mg of naphthoquine in a fixed oral dose (ARCO tablet). The regimen for children will be calculated according to the body weight (20mg artemisinin + 8mg naphthoquine per kg body weight in a fixed oral dose(ARCO tablet)).

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Sat Dec 16 09:21:55 GMT 2023` Edited by `admin` on `Sat Dec 16 09:21:55 GMT 2023`
Record UNII	TRY8UD4E2H
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NAPHTHOQUINE

Common Name

English

1-NAPHTHALENOL, 4-((7-CHLORO-4-QUINOLINYL)AMINO)-2-(((1,1-DIMETHYLETHYL)AMINO)METHYL)-5,6,7,8-TETRAHYDRO-

Systematic Name

English

4-(7-CHLORO-4-AMINOQUINOLINE)-2-TERT-BUTYLAMINOMETHYL-5,6,7,8-4HYDRO-1-NAPHTHOL

Systematic Name

English

4-((7-CHLORO-4-QUINOLINYL)AMINO)-2-(((1,1-DIMETHYLETHYL)AMINO)METHYL)-5,6,7,8-TETRAHYDRO-1-NAPHTHALENOL

Systematic Name

English

Naphthoquine [WHO-DD]

Common Name

English

Code System Code Type Description

DAILYMED

TRY8UD4E2H